IBDEI165 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20901,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,20901,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,20901,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,20902,0)
 ;;=202.90^^118^1256^17
 ;;^UTILITY(U,$J,358.3,20902,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20902,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,20902,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,20902,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,20903,0)
 ;;=200.30^^118^1256^23
 ;;^UTILITY(U,$J,358.3,20903,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20903,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,20903,1,8,0)
 ;;=8^Marginal Zone Lymphoma
 ;;^UTILITY(U,$J,358.3,20903,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,20904,0)
 ;;=200.40^^118^1256^22
 ;;^UTILITY(U,$J,358.3,20904,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20904,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,20904,1,8,0)
 ;;=8^Mantle Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,20904,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,20905,0)
 ;;=200.50^^118^1256^32
 ;;^UTILITY(U,$J,358.3,20905,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20905,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,20905,1,8,0)
 ;;=8^Prim CNS Lymphoma
 ;;^UTILITY(U,$J,358.3,20905,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,20906,0)
 ;;=200.60^^118^1256^4
 ;;^UTILITY(U,$J,358.3,20906,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20906,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,20906,1,8,0)
 ;;=8^Anaplastic Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,20906,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,20907,0)
 ;;=200.70^^118^1256^13
 ;;^UTILITY(U,$J,358.3,20907,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20907,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,20907,1,8,0)
 ;;=8^Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,20907,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,20908,0)
 ;;=200.80^^118^1256^31
 ;;^UTILITY(U,$J,358.3,20908,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20908,1,1,0)
 ;;=1^200.80
 ;;^UTILITY(U,$J,358.3,20908,1,8,0)
 ;;=8^Oth Named Variants
 ;;^UTILITY(U,$J,358.3,20908,2)
 ;;=^176827
 ;;^UTILITY(U,$J,358.3,20909,0)
 ;;=201.00^^118^1256^9
 ;;^UTILITY(U,$J,358.3,20909,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20909,1,1,0)
 ;;=1^201.00
 ;;^UTILITY(U,$J,358.3,20909,1,8,0)
 ;;=8^Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,20909,2)
 ;;=^265557
 ;;^UTILITY(U,$J,358.3,20910,0)
 ;;=201.10^^118^1256^10
 ;;^UTILITY(U,$J,358.3,20910,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20910,1,1,0)
 ;;=1^201.10
 ;;^UTILITY(U,$J,358.3,20910,1,8,0)
 ;;=8^Hodgkin's Granuloma
 ;;^UTILITY(U,$J,358.3,20910,2)
 ;;=^58273
 ;;^UTILITY(U,$J,358.3,20911,0)
 ;;=201.20^^118^1256^12
 ;;^UTILITY(U,$J,358.3,20911,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20911,1,1,0)
 ;;=1^201.20
 ;;^UTILITY(U,$J,358.3,20911,1,8,0)
 ;;=8^Hodgkin's Sarcoma
 ;;^UTILITY(U,$J,358.3,20911,2)
 ;;=^265560
 ;;^UTILITY(U,$J,358.3,20912,0)
 ;;=201.40^^118^1256^15
 ;;^UTILITY(U,$J,358.3,20912,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20912,1,1,0)
 ;;=1^201.40
 ;;^UTILITY(U,$J,358.3,20912,1,8,0)
 ;;=8^Lymphocytic-Histiocytic
 ;;^UTILITY(U,$J,358.3,20912,2)
 ;;=^265549
 ;;^UTILITY(U,$J,358.3,20913,0)
 ;;=201.50^^118^1256^30
 ;;^UTILITY(U,$J,358.3,20913,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20913,1,1,0)
 ;;=1^201.50
 ;;^UTILITY(U,$J,358.3,20913,1,8,0)
 ;;=8^Nodular Sclerosis
 ;;^UTILITY(U,$J,358.3,20913,2)
 ;;=^265555
 ;;^UTILITY(U,$J,358.3,20914,0)
 ;;=201.60^^118^1256^24
 ;;^UTILITY(U,$J,358.3,20914,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20914,1,1,0)
 ;;=1^201.60
 ;;^UTILITY(U,$J,358.3,20914,1,8,0)
 ;;=8^Mixed Cellularity
 ;;^UTILITY(U,$J,358.3,20914,2)
 ;;=^265551
